Voretigene Neparvovec

Midwest CEPAC
January 25, 2018 10am-4pm CT

Courtyard Marriott at Briarcliff
4000 North Mulberry Drive
Kansas City, MO

Recording: Evidence Presentation and Public Comments Recording: Voting Session Recording: Policy Roundtable

The Midwest CEPAC convened to deliberate on ICER's report on voretigene neparvovec (LuxturnaTM, Spark Therapeutics).

Key Dates

Associated Materials

06/16/2017 – 07/06/2017
Open Input Period
07/10/2017
Draft Scoping Document
07/10/2017
Stakeholder List
07/10/2017 – 07/31/2017
Public Comments
08/07/2017
Revised Scoping Document
09/11/2017
Model Analysis Plan
09/11/2017
Research Protocol
11/14/2017
Draft Evidence Report
11/14/2017
Draft Voting Questions
11/14/2017 – 12/13/2017
Public Comments
01/12/2018
Response to Comments
01/12/2018
Revised Voting Questions
01/12/2018
Evidence Report
01/25/2018
Meeting Agenda
01/25/2018
Evidence Presentation
02/14/2018
Final Evidence Report and Meeting Summary
02/14/2018
Report-at-a-Glance